CRDL vs. FRX, VBV, CUS, AIM, GPH, IPA, APM, GXE, CGC, and MDNA
Should you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include Fennec Pharmaceuticals (FRX), VBI Vaccines (VBV), Chemtrade Electrochem Inc, (CUS), Aimia (AIM), Graphite One (GPH), ImmunoPrecise Antibodies (IPA), Andean Precious Metals (APM), Gear Energy (GXE), Canadian Gold (CGC), and Medicenna Therapeutics (MDNA). These companies are all part of the "pharmaceutical products" industry.
Cardiol Therapeutics vs. Its Competitors
Fennec Pharmaceuticals (TSE:FRX) and Cardiol Therapeutics (TSE:CRDL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.
In the previous week, Fennec Pharmaceuticals had 13 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 13 mentions for Fennec Pharmaceuticals and 0 mentions for Cardiol Therapeutics. Fennec Pharmaceuticals' average media sentiment score of 0.52 beat Cardiol Therapeutics' score of 0.00 indicating that Fennec Pharmaceuticals is being referred to more favorably in the media.
Fennec Pharmaceuticals has a beta of 2.479494, indicating that its share price is 148% more volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 0.855752, indicating that its share price is 14% less volatile than the S&P 500.
Cardiol Therapeutics has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -2.30%. Fennec Pharmaceuticals' return on equity of 29.94% beat Cardiol Therapeutics' return on equity.
Fennec Pharmaceuticals has higher revenue and earnings than Cardiol Therapeutics. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.
14.4% of Fennec Pharmaceuticals shares are held by institutional investors. Comparatively, 0.8% of Cardiol Therapeutics shares are held by institutional investors. 16.2% of Fennec Pharmaceuticals shares are held by insiders. Comparatively, 4.6% of Cardiol Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Fennec Pharmaceuticals beats Cardiol Therapeutics on 12 of the 14 factors compared between the two stocks.
Get Cardiol Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiol Therapeutics Competitors List
Related Companies and Tools
This page (TSE:CRDL) was last updated on 10/14/2025 by MarketBeat.com Staff
